ORUKA THERAPEUTICS INC

Company Overview

Oruka Therapeutics (ORKA) is a clinical-stage biotechnology company developing engineered monoclonal antibodies for psoriasis and related inflammatory/immunology indications, with lead programs ORKA-1001 (IL-23 p19) and ORKA-1002 (dual IL-17A/F) designed for extended half-life and infrequent maintenance dosing. The company is development-focused with no internal manufacturing or commercialization infrastructure, relying on license agreements (Paragon), third-party CMOs/CMOs (WuXi), and collaboration milestones/royalties; it has incurred large upfront R&D spending and holds substantial cash following large 2024 financings. Clinical catalysts include healthy volunteer PK readouts H2 2025 and patient efficacy data H2 2026, and material near-term sensitivity to clinical, regulatory, manufacturing and reimbursement developments typical of biotech.

Executive Compensation Practices

Compensation is likely equity-heavy and milestone-driven: management has signaled substantial stock-based compensation ( ~$12M in the reported period, including $10.4M related to a Paruka warrant) and the company treats option/license exercises and warrants as material contributors to noncash expense. Given the company’s profile—no product revenue, rapid R&D spending, and milestone-dependent value—long‑term incentives (options, RSUs, warrants and milestone-based awards) will dominate total pay, with base salaries comparatively modest and increases tied to program advancement (IND/CTA filings, Phase 1/2 starts, efficacy readouts). Accounting complexities (PWERM/OPM valuations historically, now market pricing post‑merger) mean reported compensation expense can be volatile; change‑in‑control or merger-related provisions and negotiated milestone payments to discovery partners may also shape executive payout timing.

Insider Trading Considerations

Insider trading activity at Oruka will likely cluster around clear binary clinical and regulatory catalysts (PK and efficacy readouts, IND/CTA acceptances, milestone triggers) and financing events (PIPE closes, reverse recapitalization), so watch Form 4 filings and trading around those dates. Because executive pay includes significant equity and warrants and a small senior team/founder ownership (Fairmount/Paragon interconnections), insider trades may reflect exercises to cover taxes or diversify after financings, and related‑party transactions can create additional timing/valuation complexity. Standard sector regulatory practices apply: Section 16 disclosure timing (Form 4), Regulation FD considerations, blackout periods prior to material data releases, and the common use (and scrutiny) of 10b5‑1 trading plans—traders should monitor filings, grant/exercise dates, and milestone accruals for informative patterns.